Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Role of Bisphosphonates in Breast Cancer Therapy
Hadar Goldvaser
, Eitan Amir
*
*
Corresponding author for this work
Oncology
Princess Margaret Hospital
Research output
:
Contribution to journal
›
Review article
›
peer-review
48
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Role of Bisphosphonates in Breast Cancer Therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Breast Cancer Treatment
100%
Bisphosphonates
100%
Metastatic Disease
50%
Zoledronic Acid
50%
Postmenopausal Women
25%
Early Disease
25%
Early Breast Cancer
25%
Treatment Duration
12%
High Dose
12%
Placebo
12%
Inconsistent Results
12%
Adverse Effects
12%
Breast Cancer
12%
Adjuvant Chemotherapy
12%
Women-only
12%
Cost Reduction
12%
Unselected Patients
12%
Serious Adverse Events
12%
Current Guidelines
12%
Renal Impairment
12%
Hypercalcemia
12%
Potential Gains
12%
Systemic Therapy
12%
Relative Benefit
12%
Breast Cancer Mortality
12%
Pain Management
12%
Tumor Grade
12%
Treatment Plan
12%
Collaborative Groups
12%
Bisphosphonate Treatment
12%
Osteonecrosis of the Jaw
12%
Osteolytic Lesions
12%
Nodal Involvement
12%
Distant Recurrence
12%
Performance Status
12%
Skeletal-related Events
12%
Bone Involvement
12%
Treatment-related Adverse Events
12%
Absolute Benefit
12%
Receptor Status
12%
Trialists
12%
Clodronate
12%
Adjuvant Bisphosphonates
12%
Dose-dense
12%
Bone Recurrence
12%
Absolute Potential
12%
Skeletal Morbidity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Bisphosphonic Acid Derivative
100%
Metastasis
40%
Zoledronic Acid
40%
Adverse Event
30%
Recurrent Disease
20%
Pamidronic Acid
20%
Disease
10%
Placebo
10%
Chemotherapy
10%
Receptor
10%
Neoplasm
10%
Hypercalcaemia
10%
Clodronic Acid
10%
Cancer Mortality
10%
Bone Atrophy
10%
Jaw Osteonecrosis
10%